Key result
Aspirin for primary prevention had no significant effect on stroke (RR 1.08; 95% CI 0.95-1.24), but decreased myocardial infarction (RR 0.74; 95% CI 0.68-0.82) and increased intracranial hemorrhage.
Why the study?
Does aspirin reduce stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease?
Population
52,251 participants without clinically recognized vascular disease pooled from 5 randomized trials of…
Comparison
Aspirin 75 to 650 mg/d vs Control (implied from randomized trials)
Design
Meta-analysis, Randomized clinical trials
Follow-up
average 4.6 years
Authors
Loading...
Aspirin warrants caution for routine primary prevention due to ICH risk without stroke benefit; extends evidence that net gains are limited to secondary prevention.
Meta-Analysis (n=52,251)
Does aspirin reduce stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease?
Effect estimate: RR 1.08 (95% CI 0.95-1.24)
In primary prevention, aspirin does not significantly reduce stroke risk but decreases myocardial infarction, while increasing the risk of intracranial hemorrhage.
Hart et al. (2000) conducted a meta-analysis in Persons without clinically recognized vascular disease (n=52,251). Aspirin was evaluated on Stroke (RR 1.08, 95% CI 0.95-1.24). Aspirin for primary prevention had no significant effect on stroke (RR 1.08; 95% CI 0.95-1.24), but decreased myocardial infarction (RR 0.74; 95% CI 0.68-0.82) and increased intracranial hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: